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Hematopoietic stem cell transplantation (HSCT) is the deﬁnite treatment for patients with thalassemia major.
A busulfan (Bu) and cyclophosphamide (Cy)ebased regimen has been the standard myeloablative chemo-
therapy, but it is associated with higher treatment-related toxicity, particularly in patients classiﬁed as high
risk by the Pesaro criteria. Treosulfan-based conditioning regimens have been found to be equally effective
and less toxic. Consequently, we analyzed the safety and efﬁcacy of treosulfan/thiotepa/ﬂudarabine (treo/
thio/ﬂu)-based conditioning regimens for allogeneic HSCT in patients with thalassemia major between
February 2010 and September 2012. We compared those results retrospectively with results in patients who
underwent previous HSCT with a Bu/Cy/antithymocyte globulin (ATG)ebased conditioning regimen. A treo/
thio/ﬂu-based conditioning regimen was used in 28 consecutive patients with thalassemia major. The median
patient age was 9.7 years (range, 2-18 years), and the mean CD34þ stem cell dose was 6.18  106/kg.
Neutrophil and platelet engraftment occurred at a median of 15 days (range, 12-23 days) and 21 days (range,
14-34 days), respectively. Three patients developed veno-occlusive disease, 4 patients developed acute graft-
versus-host disease (GVHD), and 2 patients had chronic GVHD. Treatment-related mortality (TRM) was 21.4%.
Two patients experienced secondary graft rejection. We compared these results with results in patients who
underwent previous HSCT using a Bu/Cy/ATG-based conditioning regimen. Twelve patients were treated with
this protocol, at a median age of 7.2 years (range, 2-11 years). One patient had moderate veno-occlusive
disease, 2 patients developed acute GVHD, 2 patients had chronic GVHD, and 2 patients experienced graft
rejection. There was no TRM in this group. We found no signiﬁcant differences between the 2 groups (treo/
thio/ﬂu vs Bu/Cy/ATG) in terms of the incidence of acute GVHD, chronic GVHD, TRM, and graft failure,
although a trend toward higher TRM was seen with the treo/thio/ﬂu regimen.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION (ATG) and carry a high rate of regimen-related toxicity. New
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the sole curative treatment for patients with thal-
assemia major (TM) [1-3]. However, the clinical outcome
after HSCT in children with TM who are classiﬁed as Pesaro
class 3 and in adults with poor performance status and/or
organ dysfunction remains unsatisfactory, owing to the high
risk of treatment-related complications or graft failure [2-5],
and the event-free survival rate is only 60% [5,6]. Even class 3
represents a heterogenous group of patients with overall
survival after HSCT, varying from 39.01% in high-risk class 3
patients to 78.3% in other class 3 patients [7]. The most
commonly used conditioning regimens incorporate busulfan
(Bu), cyclophosphamide (Cy), and antithymocyte globulinedgments on page 494.
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12.11.007treatment strategies have been shown to improve outcomes
in high-risk patients [5,6]. In patients with class 3 thalas-
semia aged <17 years, the protocol 26 regimen (with
hydroxyurea, azathioprine, and ﬂudarabine added to Bu
and Cy) was well tolerated, with 93% survival, and the inci-
dence of post-HSCTgraft failure decreased from30% to 8% [8].
Low liver toxicity has also been observed with the use of i.v.
busulfan in children with thalassemia undergoing HSCT [9].
Bernardo et al. [10] reported that treosulfan-based
conditioning regimens are safe and effective in patients
with thalassemia major. To minimize regimen-related
toxicity, we treated patients with thalassemia major with a
treosulfan/thiotepa/ﬂudarabine (treo/thio/ﬂu)-based condi-
tioning regimen in a prospective manner and compared
the results retrospectively with those in the patients treated
earlier with a Bu/Cy/ATG- based regimen at the same center.Study Design
This study involved an analysis of 28 consecutive patients
with thalassemia major who underwent HLA-matched
allogeneic HSCT using a treo/thio/ﬂu-based conditioning
Figure 1. Thalassemia-free survival by conditioning regimen.
Table 1
Characteristics of Patients Undergoing HSCT with Bu/Cy/ATG-Based and
Treo/Thio/Flu-Based Conditioning Regimens
Characteristic Bu/Cy/ATG
(n ¼ 12)
Thio/Treo/Flu
(n ¼ 28)
P value
Sex, n .68
Male 8 15
Female 4 13
Age, y, median (range) 7 (2-11) 9.6 (2-18)
Pesaro class, n .24
Class 1 1 0
Class 2 4 7
Class 3 7 21
CD34þ cells,  106/kg, mean 7.61 6.76 .32
VOD, n 1 3 .82
Neutrophil engraftment,
days, mean
16 15 .87
Acute GVHD, n 2 4 .77
Chronc GVHD, n 1 2 .66
Graft failure, n 2 2 .73
Death, n 0 6 .07
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speciality Hospital, New Delhi, between February 2010
and September 2012. Data for 12 patients who underwent
HSCT using a Bu/Cy/ATG-based regimen were also analyzed
retrospectively and compared with the patients receiving
a treo/thio/ﬂu-based protocol. Informed consent from
parent/guardian was obtained before a patient was enrolled.
The study was approved by the hospital’s Institutional
Review Board and Ethical Committee.
All patients in the treo/thio/ﬂu group received the same
conditioning regimen, comprising i.v. thiotepa 8 mg/kg on
day -6, treosulfan 14 g/m2/day on day -5 to day -3, and ﬂu-
darabine 40 mg/m2/day on day -5 to day -2. Patients in the
Bu/Cy/ATG group received oral busulfan 3.5 mg/kg/day on
day -9 to day -6, cyclophosphamide 50 mg/kg/day on day -5
to day -2, and ATG 30 mg/kg/day on day -4 to day -2. Graft-
versus-host disease (GVHD) prophylaxis included cyclo-
sporine (2.5 mg/kg i.v. twice daily) andmethotrexate (10 mg/
m2 i.v. on day þ1 and 7 mg/m2 on days þ3, þ6, and þ11). All
patients received cyclosporine for 9 to 12 months post-HSCT,
with trough plasma cyclosporine levels maintained at 200 to
350 ng/mL. Acute and chronic GVHD were diagnosed and
graded according to the Seattle criteria. Veno-occlusive
disease (VOD), also called sinusoidal obstruction syndrome,
was diagnosed according to clinical criteria as the presence
of 2 of the following before day 21 post-HSCT: (1) hyper-
bilirubinemia (bilirubin >2.0 mg/dL), (2) painful hepato-
megaly, and (3) unexplained weight gain (>2% from
baseline). Severity of VOD was classiﬁed as mild, moderate,
or severe. Neutrophil recovery was deﬁned as the ﬁrst of 3
consecutive days with an absolute neutrophil count 0.5 
109/L and a platelet count 20  109/L unsupported for
7 days. Chimerism was evaluated by ﬂuorescein in situ
hybridization in sex-mismatched transplantations and by
PCR in others.Statistical Analysis
The primary study endpoints were to determine the
incidences of graft failure and treatment-related mortality
(TRM) after HSCT. Secondary endpoints included the inci-
dence and severity of VOD and acute and chronic GVHD. The
incidences of relapse, TRM, and GVHD were calculated using
cumulative incidence estimates. The differences in outcomes
between the 2 groups (treo/thio/ﬂu group and Bu/Cy/ATG
group) were analyzed as well. Fisher’s exact test was used fordiscrete variables, and the t-test was used for continuous
variables. The log-rank test was used for the difference in
survival outcome between the 2 groups. A P value < .05 was
considered statistically signiﬁcant.
RESULTS
Twenty-eight consecutive patients with thalassemia
major who underwent allogeneic HSCT using a treo/thio/ﬂu-
based conditioning regimen were evaluated. The median
patient age was 9.6 years (range, 2-18 years). The group
included 15 males and 13 females. Patients were classifed
according to the Pesaro classiﬁcation scheme based on liver
size, adequacy of chelation, and hepatic ﬁbrosis. Seven
patients were in Pesaro class 2, and 21 patients were in
Pesaro class 3. When stratiﬁed according to age (7 years)
and liver size (5 cm) [7], 11 of 21 class 3 patients (52.4%)
were considered high risk. The stem cell source was ﬁl-
grastim (granulocyte colony-stimulating factor)-mobilized
peripheral blood in 2 patients, bone marrow in 21 patients,
and bonemarrow plus cord blood in 5 patients. The mean CD
34þ stem cell dose was 6.18  106/kg. Neutrophils and
platelets engrafted at a median of 15 days (range,12-23 days)
and 21 days (range, 14-34 days), respectively. Three patients
had a major blood group mismatch, 2 patients had a bidi-
rectional blood group mismatch, and 4 patients had a minor
blood group mismatch. The median duration of follow-up
was 387 days (range, 37-930 days). Nineteen patients
developed World Health Organization stage 1-3 oral muco-
sitis (stage 3 in 2 patients). Only 3 patients required total
parenteral nutrition, 2 with stage IV gut GVHD and 1 with
stage 3 oral mucositis. No renal, pulmonary, cardiac, or
central nervous system toxicities were observed. Four
patients developed grade II-IV acute GVHD, for a cumulative
incidence of 14.3% (95% conﬁdence interval [CI], 3.6%-26.2%).
Two patients had grade II-IV skin GVHD, and 2 patients had
grade II-IV gut GVHD. Three patients developed severe VOD.
Six deaths occurred in the treo/thio/ﬂu group, including
3 due to VOD (on daysþ17,þ27, andþ29), 2 due to acute gut
GVHD (on days þ37 and þ60), and 1 due to sepsis, for
a cumulative incidence of TRM of 21.4% (95% CI, 4%-35.8%).
The cumulative incidence of limited chronic GVHD was 10%
(95% CI, 1%-16%). The median hospital stay was 37 days
Figure 2. Overall survival by type of conditioning regimen.
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a median follow-up of 387 days (range, 37-930 days), and all
but 2 patients were transfusion-independent with sustained
donor engraftment. Graft rejection occurred in 2 patients, on
days þ369 and þ414. Twelve patients were prescribed
regular phlebotomy therapy. Thalassemia-free survival and
overall survival were 71.4% and 78.5%, respectively. Median
chimerism in 18 of the 20 evaluable patients in the treo/thio/
ﬂu group at last follow-up was 100% (range, 31%-100%).
Fourteen of these patients achieved sustained full-donor
chimerism, and 4 patients had mixed chimerism.
We also retrospectively analyzed our data on patients who
hadundergonepreviousHSCTatour centerwitha Bu/Cy/ATG-
based conditioning regimen. Twelve patients, median age 7.2
years (range, 2-11 years), were treatedwith this protocol. One
patienthadmoderateVOD, and2patientsdevelopedacutegut
GVHD; all 3 patients recovered. Two patients developed
limited chronic GVHD that responded to steroids. Rejection
occurred in 2 patients in the Bu/Cy/ATG group (on days þ154
andþ210). There was no TRM in this group. The thalassemia-
free survival and overall survival were 83.3% and 100%,
respectively. Median chimerism in 8 of the 10 evaluable
patients in the Bu/Cy/ATG group at last follow-up was 100%
(range, 61%-100%). Six of these patients achieved sustained
full-donor chimerism, and 2 patients had mixed chimerism.
There were no signiﬁcant differences in the incidence of
acute GVHD, chronic GVHD, TRM, and graft failure between
the treo/thio/ﬂu and Bu/Cy/ATG groups (Table 1 and
Figure 1), although a trend toward higher TRM was seen in
the treo/thio/ﬂu group (Figure 2). Two patients in each group
had an HLA 5/6-matched donor; these patients demon-
strated no difference in morbidity or mortality compared
with the total cohort.DISCUSSION
Allogeneic HSCT remains the sole available curative
treatment for patients with thalassemia major [1]. The best
candidates for HSCT are patients with an HLA-identical
sibling donor, limited iron overload, and an absence of
severe hepatic complications [1,2,4]. Bu/Cy/ATG-based
conditioning regimens are most commonly used in patients
with thalassemia major. High-risk patients are known to beat increased risk for treatment-related morbidity and TRM
with Bu/Cy/ATG-based regimens. Lower-toxicity treo/thio/
ﬂu-based regimens have been found to be equally effective,
with less TRM [10]. Bu-based regimens have been associated
with increased treatment-related morbidity (ie, VOD and
obliterans bronchiolitis), particularly in Pesaro class 3
patients [4]. The probability of overall event-free survival
with this regimen is 89% to 97% in patients with low-risk
disease and 80% to 87% in those with high-risk disease [11].
In a study of 179 patients treated with a Bu/Cy-based
regimen [12], 17 patients (9.5%) experienced graft failure,
and the day þ100 probability of acute GVHD and 5-year
probability of chronic GVHD were 38% and 13%, respec-
tively. The 5-year probabilities of overall and disease-free
survival were 64% and 62%, respectively, for Pesaro risk
class 3. The protocol 26 regimen and i.v. Bu-based regimens
have also been used in an attempt to reduce graft failure and
liver toxicity [8,9], with encouraging results. Treosulfan has
been used as a conditioning regimen in patients with thal-
assemia major based on its signiﬁcant lytic action in hema-
topoietic progenitors [13]. Bernardo et al. [10] reported the
results of 60 patients with thalassemia (median age, 7 years)
undergoing allogeneic HSCT with a treo/thio/ﬂu-based
conditioning regimen. They found cumulative incidences of
acute GVHD, graft failure, and TRM of 14%, 9%, and 7%,
respectively, compared with our values of 14%, 7.14%, and
21.4%. Although other studies [14,15] have also reported
reduced TRM owing to treo/ﬂu-based conditioning, the
higher TRM in our study was likely related to the fact that
52.4% of our patients in class 3 were considered high risk.
In this study, the cumulative incidences of acute GVHD,
chronic GVHD, and TRM were 14.3%, 7%, and 21.4% respec-
tively, in the treo/thio/ﬂu group, compared with 16.6%, 8.3%,
and 0% in the Bu/Cy/ATG group (Table 1 and Figure 1). The
incidence of VOD did not differ in the 2 groups (P ¼ .82). We
noted a trend toward increasing TRM in the treo/thio/ﬂu
group compared with the Bu/Cy/ATG group (P ¼ .07)
(Figure 2). We conclude that there is no signiﬁcant difference
between the 2 groups in the incidence of acute GVHD,
chronic GVHD, TRM and graft failure, although the treo/thio/
ﬂu demonstrated a trend toward a higher TRM. Our sample
size was small; however, randomized trials are needed to
identify statistically signiﬁcant differences between the 2
conditioning regimens.
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The therapeutic efﬁcacy of allogeneic peripheral blood stem cell transplantation (PBSCT) for hematological
malignancies relies largely on the graft-versus-leukemia (GVL) effects exerted by the donor CD3 cells, but there
is a risk of onset of uncontrolled graft-versus-host disease (GVHD). Regulatory T cells (Tregs) (CD4þCD25high
Foxp3þ) are believed to maintain tolerance and to inhibit acute GVHD (aGVHD) after allogeneic PBSCT.
Nevertheless, when looking at post-allotransplantation patient outcomes, although the impact of aGVHD on
survival is amply documented, so far there is no evidence that the donor graft CD3/Tregs ratiomayaffect overall
survival (OS), nonrelapse mortality (NRM), disease-free survival (DFS), and relapse rates. Our aimwas to study
the possible impact of the gCD3/Tregs ratio on survival after myeloablative allogeneic PBSCT. We analyzed 74
consecutive patients diagnosed with acute myeloid leukemia (n ¼ 62), acute lymphoblastic leukemia (n¼ 10),
and chronic myeloid leukemia (n ¼ 2) who underwent transplantation with unmanipulated PBSCs from
a human leukocyte antigeneidentical related donor (n¼ 48) or a human leukocyte antigeneidentical unrelated
donor (n¼ 26). Patients were subdivided into a high gCD3/Tregs ratio (36) group (HR group, n¼ 30) and a low
gCD3/Tregs ratio (<36) group (LR group, n¼ 44). The OS, DFS, NRM, and relapse rates at 3 years were 53%, 51%,
29%, and 34%, respectively. Comparing the LR and HR groups, a statistically signiﬁcant difference was
demonstrated for the 3-year OS, DFS, and NRM rates (65% vs 31%, P¼ .0001; 67 versus 26%, P¼ .0001; 5% versus
71%, P < .0001, respectively) but not for relapse (30% vs 25%, P ¼ ns). By multivariate analysis, LR signiﬁcantly
predicted better OS (P ¼ .019), DFS (P ¼ .003), and NRM (P ¼ .05), whereas there was no statistically signiﬁcant
association between LR and relapse (P¼ .155). Overall, our datamay suggest that LR preserves GVL effects but is
also protective against aGVHD in allotransplantation patients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION models [2]. The pathophysiological link between GVHD and
The contribution of regulatory T cells (Tregs) to post-
transplantation immunological reconstitution has been
clearly established, given their impact on T cell immunity [1]
and on modulating graft-versus-host disease (GVHD) while
preserving graft-versus-leukemia (GVL) effects in mouseimmune reconstitution is well deﬁned [3,4]. Therefore, given
that acute GVHD (aGVHD) is triggered by alloreactive mature
donor CD3 T cells [5,6] and antagonized by Tregs [7,8], the
immunity of patients undergoing allotransplantation might
depend on the ratio between these two cellular populations,
as we have already suggested in humans [9], in line with
murine experimental models of aGVHD [10,11].
Moreover, it is well known that, apart from inducing
prolonged immunosuppression [12] and a graft failure risk
[13], T cell depletion of the donor graft results in a higher
leukemia relapse rate [14]. Nevertheless, when looking at the
outcomes of patients undergoing allotransplantation,
although the impact of human leukocyte antigen (HLA)
incompatibility (and of the consequent aGVHD) on patient
